BLU-222

CAS No. 2888704-84-3

BLU-222( —— )

Catalog No. M37524 CAS No. 2888704-84-3

BLU-222 is an orally available but selective cell cycle protein-dependent kinase (CDK2) inhibitor with antitumor activity for the study of ovarian and uterine cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 319 In Stock
5MG 282 In Stock
10MG 503 In Stock
25MG 937 In Stock
50MG 1237 In Stock
100MG 1665 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BLU-222
  • Note
    Research use only, not for human use.
  • Brief Description
    BLU-222 is an orally available but selective cell cycle protein-dependent kinase (CDK2) inhibitor with antitumor activity for the study of ovarian and uterine cancer.
  • Description
    BLU-222 is an orally available but selective cell cycle protein-dependent kinase (CDK2) inhibitor with antitumor activity for the study of ovarian and uterine cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2888704-84-3
  • Formula Weight
    365.34
  • Molecular Formula
    C15H17F2N7O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    FC(F)OC1=CC(=NN1)NC2=NC3=C(N=C2)C=NN3CC4CCOCC4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • (S)-PF-06873600

    (S)-PF-06873600 is the S enantiomer of PF-06873600 which is an inhibitor of CDK.

  • AZ5576

    AZ5576, a potent and highly selective CDK9 inhibitor, can be used for research on Hematological Malignancy .

  • Palbociclib

    A potent and selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM; no inhibition for CDK2A (IC50>5 uM); inhibits MDA-MB453 cells with IC50 of 0.16 uM.